Product Details
Product Name:
ST7612AA1 |
CAS No.:
1428535-92-5 |
Purity:
100% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | ST7612AA1 |
Description | ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria. |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (135.63 mM)
|
Keywords | MRT 92 | MRT92. | ST7612AA1 |
Inhibitors Related | Stavudine | 5-Fluorouracil | Inosine pranobex | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Tenofovir Disoproxil Fumarate | Decanedioic acid | Tenofovir |
Related Compound Libraries | Anti-Parasitic Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:73785-31-6
$56.00 / 1mg
-
CAS:2293-21-2
$86.00 / 1mg
-
CAS:123997-26-2
$45.00 / 50mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |